Navigation Links
InspireMD Postpones $40 Million Registered
Date:11/16/2012

TEL AVIV, Israel, November 16, 2012 /PRNewswire/ --

InspireMD, Inc. ("InspireMD" or the "Company") announced that, based on recent adverse market conditions, it has chosen to postpone its planned registered public offering of $40 million worth of its shares of common stock until a later date.  

InspireMD's registration statement on Form S-1, as filed with the Securities and Exchange Commission, has not been withdrawn and the Company expects to continue to evaluate the timing for the offering.

About InspireMD, Inc.

InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the OTC under the ticker symbol NSPR.

About MGuard™ Embolic Protection Coronary Stent

MGuard™ EPS combines a coronary stent merged with an embolic protection specifically designed for acute MI patients. The embolic protection is comprised of an ultra-thin polymer micron net that is integrated with the stent. The MGuard EPS is designed to provide outstanding and lifelong embolic protection, without affecting deliverability. MGuard EPS is CE Mark approved. MGuard™ is not approved for sale in the U.S. by the U.S. Food and Drug Administration at this time.

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Transition Report on From 10-K/T and its Quarterly Reports on Form 10-Q.  Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

For additional information:
InspireMD Desk
Redington, Inc.
+1-212-926-1733
+1-203-222-7399
inspiremd@redingtoninc.com


'/>"/>
SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
2. InspireMD Appoints Dr. James Barry to Its Board of Directors
3. InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
4. InspireMD to Present at JMP Securities Healthcare Conference on July 12th in New York
5. InspireMD Reports 2012 Fiscal Year Results
6. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
7. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
10. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
11. BioPower Systems Awarded $5 Million from Victorian Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or ... China , today announced that its board of ... date of the plan from March 27, 2017 to March 27, ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/24/2017)... LEXINGTON, Mass. , March 24, 2017 ... pipeline of immune checkpoint antibodies and cancer vaccines, today ... The 7 th  Annual William Blair and Maidstone ... Event Space Alexandria Center in New York, ... March 29 at 9:40 am: ...
(Date:3/23/2017)... Research and Markets has announced the addition of ... offering. ... The Global Market for Bioproducts Should Reach $714.6 Billion ... of 8.9%, This research report quantifies the ... product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite ...
(Date:3/23/2017)... , March 23, 2017  GlobeImmune, Inc. today ... for the sale of 12,835,490 shares of its common ...  ecosystem of companies. In connection with the sale of its ... in cash and issue to GlobeImmune 200,000 shares, an ... "We are pleased to enter into ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
Breaking Biology News(10 mins):